Ana Patricia Ferreira
About Ana Patricia Ferreira
Ana Patricia Ferreira is the Scientific Associate Director at Bristol-Myers Squibb in the United Kingdom, with over 20 years of experience in the pharmaceutical and biotechnology industries.
Title and Current Role
Ana Patricia Ferreira currently holds the position of Scientific Associate Director at Bristol-Myers Squibb in the United Kingdom. In this role, she is involved in leading scientific teams and managing complex research projects, with a significant focus on the development and implementation of Risk Evaluation and Mitigation Strategies (REMS) for certain medications.
Professional Background and Career Path
Ana Patricia Ferreira has been with Bristol-Myers Squibb for over a decade. She began her career at the company as a Senior Research Investigator from 2011 to 2015. She then advanced to the role of Principal Scientist, which she held from 2015 to 2019. In 2019, she assumed her current role as Scientific Associate Director. Before joining Bristol-Myers Squibb, Ferreira worked as a Chemometrician at GSK from 2007 to 2011, where she applied chemometric techniques to enhance drug development processes.
Educational Background
Ana Patricia Ferreira studied at Instituto Superior Técnico, where she obtained her Graduation in Chemical Engineering from 1996 to 2002. She further pursued her education at the same institute to achieve a PhD in Biotechnology, which she completed from 2002 to 2006.
Expertise in Chemometrics
Ana Patricia Ferreira specializes in chemometrics, a field that applies mathematical and statistical methods to chemical data. Her work in this area has been pivotal, particularly during her tenure at GSK, where she applied these techniques to improve drug development processes. Her expertise in chemometrics continues to inform her work in pharmaceutical research and development.
Commitment to Patient Safety
Ana Patricia Ferreira is deeply committed to patient safety and public health. Her responsibilities at Bristol-Myers Squibb include developing and implementing REMS programs to ensure the safe use of medications with serious risks, such as thalidomide, lenalidomide, and pomalidomide. Through these efforts, she helps patients access necessary medications while mitigating potential serious risks associated with their use.